| Literature DB >> 31028568 |
Dongdong Wu1,2, Wenke Tian1,2, Jianmei Li1,2, Qianqian Zhang1,2, Honggang Wang1,2, Lei Zhang1,2, Zhongwen Xie3, Ailing Ji4,5, Yanzhang Li6,7.
Abstract
Thyroid carcinoma is the most common endocrine malignancy, and the incidence of thyroid carcinoma is increasing in recent decades. CYYGQSKYC (P6), a nonapeptide with anti-lymphangiogenic effect by its binding to VEGFR-3 and selectively inhibiting VEGF-C binding to VEGFR-3, could suppress the migration and invasion of cancer cells. LSPPRYP (P9) acts as an effective bFGF/FGFR antagonist and inhibits the growth of the murine melanoma B16-F10 cells. In order to increase the anti-tumor effects of P6 and P9, we connected P6 with P9 via a flexible linker Gly-Gly-Gly (GGG) to reconstruct a novel peptide P11, CYYGQSKYCGGGLSPPRYP. In the present study, the mechanism of action of peptide P11 on the growth of human thyroid carcinoma cells both in vitro and in vivo was determined. Our results showed that peptide P11 inhibited the proliferation, viability, migration, and invasion of human thyroid carcinoma cells. Peptide P11 increased the apoptosis and decreased the protein levels of p-PI3K, p-AKT, and p-mTOR in human thyroid carcinoma cells. In addition, P11 could effectively inhibit the growth of human thyroid carcinoma xenograft tumors in nude mice. In conclusion, peptide P11 could inhibit the growth of human thyroid carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway. Novel peptides can be designed and applied for the treatment of various types of cancer.Entities:
Keywords: Apoptosis; Peptide P11; Signaling pathway; Thyroid carcinoma
Mesh：
Substances：
Year: 2019 PMID： 31028568 DOI： 10.1007/s11033-019-04698-7
Source DB: PubMed Journal: Mol Biol Rep ISSN： 0301-4851 Impact factor: 2.316